Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Zymedi
Incheon, South Korea
A
11-50 Employees
2019
Key takeaway
ZYMEDI is focused on developing innovative therapies for challenging diseases, utilizing AI-assisted lead discovery and optimization to create first-in-class drugs. Their commitment to addressing unmet medical needs through precision medicine highlights their unique approach to drug discovery.
Reference
Core business
Zymedi - Home - Zymedi
ZYMEDI is expanding the promise of precision medicine OUR SCIENCE OUR PLATFORM OUR SOLUTION OUR APPROACH ZYMEDI is expanding the promise of precision medicine
Spidercore Inc.
Daejeon, South Korea
A
1-10 Employees
2020
Key takeaway
Spidercore's S.Core platform utilizes a hyper-scale AI engine to analyze nucleotides, aiming to enhance gene therapy development. Their focus on AI-driven decision-making in biomedical care promises improved accuracy and efficiency in clinical practices.
Reference
Core business
Spidercore Inc.
Brightonix Imaging
Pyeongtaek-si, South Korea
A
1-10 Employees
2016
Key takeaway
The company is a global leader in innovative biomedical imaging solutions, including AI applications, which may be relevant to advancements in AI drug discovery. Their expertise in imaging technologies like PET could enhance the drug development process.
Reference
Product
AI Solutions - products - BRIGHTONIX IMAGING
PET/MRI
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
AIMMO
Seongnam-si, South Korea
A
51-100 Employees
2016
Key takeaway
AIMMO is revolutionizing the AI landscape with its advanced machine learning workflows and tailored AI capabilities, which could have significant implications for AI drug discovery. Their focus on high-quality, structured data sets and 99.9% accuracy can enhance the efficiency and effectiveness of machine learning operations in the pharmaceutical sector.
Reference
Service
AIMMO | AI Data Company
AIMMO Core, Enabling a data-powered tomorrow, AI Data company AIMMO
Insilicogen
Yongin-si, South Korea
A
11-50 Employees
2005
Key takeaway
Insilicogen has built a robust bio big data infrastructure over the past 20 years, positioning itself as a leader in data production, archiving, modeling, and analysis, which are crucial processes in AI drug discovery.
Reference
Product
Solution | Insilicogen, Inc.
New Era for Bioinformatics
Galux
Seoul, South Korea
A
11-50 Employees
2020
Key takeaway
Galux is transforming drug discovery through its innovative in silico technology that integrates physics, chemistry, and artificial intelligence. Their protein structure modeling platform, "GALAXY," is recognized as one of the leading methods globally, enhancing the drug development process.
Reference
Core business
갤럭스
Galux는 물리화학과 인공지능을 독창적으로 융합한 신약 설계 소프트웨어로 신약개발과정의 혁신을 이루고자 합니다
DongBangFTL
Hwaseong-si, South Korea
A
51-100 Employees
1990
Key takeaway
DongBangFTL is a leading company in the API industry, emphasizing its innovative research facilities and commitment to new drug development. With a strong export presence and established partnerships, they create an ecosystem for collaboration in the pharmaceutical sector.
Reference
Core business
DongbangFTL
AIRS Medical
Seoul, South Korea
A
11-50 Employees
2018
Key takeaway
AIRS Medical Inc. is revolutionizing the healthcare industry with its innovative, data-driven solutions, including an automated venipuncture system and an award-winning MRI enhancement technology. Their commitment to digital transformation and efficiency in medical procedures positions them as a key player in advancing healthcare delivery.
Reference
Core business
AIRS Medical Inc. – Official website of AIRS Medical Inc., Healthcare AI-Solution provider offering MRI Enhancement solution, Blood collection aid robits.
Onegene Biotechnology
Seongnam-si, South Korea
A
- Employees
2016
Key takeaway
Onegene Biotechnology is focused on advancing drug development, particularly through multi-target approaches, which may align with interests in AI drug discovery. Their expertise in dissecting disease microenvironments and developing multi-specific drugs positions them at the forefront of innovative treatment strategies.
Reference
Core business
ONEGENE BIOTECHNOLOGY
Mediwhale
Seoul, South Korea
A
11-50 Employees
2016
Key takeaway
The company focuses on early health risk detection through AI-powered retinal scans, which can predict various diseases, including cardiovascular and kidney conditions. Their Reti-Intelligence platform utilizes deep learning to analyze retinal images, providing a proactive approach to preventive healthcare.
Reference
Core business
Mediwhale | AI diagnostic solution
We believe that early detection is the best prevention. Our innovative diagnostic technology helps you take action before symptoms appear.
Technologies which have been searched by others and may be interesting for you:
The AI drug discovery industry in South Korea presents a rapidly evolving landscape marked by significant opportunities and unique challenges. One key consideration is the regulatory framework, which is becoming increasingly supportive of innovative technologies. The Ministry of Food and Drug Safety (MFDS) oversees the approval process, emphasizing the need for compliance with both national and international standards. Researchers and companies must also navigate challenges such as data privacy concerns and the integration of AI technology with traditional drug development processes. The competitive landscape is characterized by collaboration between academia and biotech firms, fostering a vibrant ecosystem for innovation. South Korea's strong investment in research and development, alongside government initiatives promoting digital healthcare, enhances the country’s global market relevance. However, companies should be aware of the potential environmental impacts associated with drug manufacturing and the importance of sustainable practices in their operations. In summary, those interested in the AI drug discovery sector should focus on understanding regulatory compliance, forging partnerships within the local ecosystem, and addressing sustainability issues to leverage the growing market effectively. Additionally, staying informed about global trends and advancements in AI technologies will be crucial for maintaining a competitive edge in this dynamic field.
Some interesting numbers and facts about your company results for Ai Drug Discovery
| Country with most fitting companies | South Korea |
| Amount of fitting manufacturers | 17 |
| Amount of suitable service providers | 5 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1990 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for Ai Drug Discovery
What are related technologies to Ai Drug Discovery?
Based on our calculations related technologies to Ai Drug Discovery are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Ai Drug Discovery?
The most represented industries which are working in Ai Drug Discovery are Biotechnology, IT, Software and Services, Medical, Other, Human Resources
How does ensun find these Ai Drug Discovery Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.